Cagrilintide vs Orforglipron

A long-acting amylin analogue developed by Novo Nordisk. On its own it produces modest weight loss; paired with semaglutide (CagriSema), it exceeds tirzepatide in trials.

Eli Lilly's oral, non-peptide GLP-1 receptor agonist. The first viable once-daily pill competing with injectable semaglutide and tirzepatide. Expected FDA approval in 2026–2027.

Cagrilintide activates amylin and calcitonin receptors, delaying gastric emptying and suppressing appetite through a mechanism complementary to GLP-1 receptor agonism.

Orforglipron is a small molecule (not a peptide) that mimics GLP-1 binding. Its oral bioavailability is the breakthrough — no injection, no cold-chain storage, no complex dosing schedule.

2.4 mg subcutaneous weekly (matched to semaglutide)

12–36 mg oral once daily (in trials)

~7 days

~25 hours

Subcutaneous

Oral

investigational

investigational

Not yet listed

Not yet listed